0 XP   0   0   0

Genmab










Financial Health of Genmab




Comparing to competitors in the industry




  Industry Rankings  


Genmab
Buy, Hold or Sell?

Should you buy, hold or sell Genmab?

I guess you are interested in Genmab. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Genmab

Let's start. I'm going to help you getting a better view of Genmab. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Genmab even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Genmab is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Genmab. The closing price on 2022-12-07 was kr3,257 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Genmab Daily Candlestick Chart

Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of Genmab.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Genmab earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Genmab to the  industry mean.
  • A Net Profit Margin of 0.0% means that kr0.00 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Genmab:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY37.9%-37.9%
TTM-5Y20.3%-20.3%
5Y20.3%10Y20.3%0.0%
1.1.2. Return on Assets

Shows how efficient Genmab is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Genmab to the  industry mean.
  • 10.8% Return on Assets means that Genmab generated kr0.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Genmab:

  • The MRQ is 10.8%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 5.9%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ10.8%TTM5.9%+4.9%
TTM5.9%YOY3.2%+2.7%
TTM5.9%5Y4.3%+1.6%
5Y4.3%10Y4.3%0.0%
1.1.3. Return on Equity

Shows how efficient Genmab is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Genmab to the  industry mean.
  • 12.1% Return on Equity means Genmab generated kr0.12 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Genmab:

  • The MRQ is 12.1%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 6.6%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ12.1%TTM6.6%+5.5%
TTM6.6%YOY3.5%+3.1%
TTM6.6%5Y4.8%+1.8%
5Y4.8%10Y4.8%0.0%

1.2. Operating Efficiency of Genmab.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Genmab is operating .

  • Measures how much profit Genmab makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Genmab to the  industry mean.
  • An Operating Margin of 0.0% means the company generated kr0.00  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Genmab:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY19.6%-19.6%
TTM-5Y8.7%-8.7%
5Y8.7%10Y8.7%0.0%
1.2.2. Operating Ratio

Measures how efficient Genmab is keeping operating costs low.

  • Below 1 is considered healthy (always compare to  industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are kr0.00 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Genmab:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000

1.3. Liquidity of Genmab.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Genmab is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to  industry mean).
  • A Current Ratio of 9.62 means the company has kr9.62 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Genmab:

  • The MRQ is 9.618. The company is very able to pay all its short-term debts. +2
  • The TTM is 13.635. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ9.618TTM13.635-4.016
TTM13.635YOY14.360-0.726
TTM13.6355Y13.402+0.233
5Y13.40210Y13.4020.000
1.3.2. Quick Ratio

Measures if Genmab is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Genmab to the  industry mean.
  • A Quick Ratio of 1.66 means the company can pay off kr1.66 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Genmab:

  • The MRQ is 1.657. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.050. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.657TTM2.050-0.393
TTM2.050YOY20.963-18.913
TTM2.0505Y11.609-9.560
5Y11.60910Y11.6090.000

1.4. Solvency of Genmab.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Genmab assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Genmab to industry mean.
  • A Debt to Asset Ratio of 0.11 means that Genmab assets are financed with 11.3% credit (debt) and the remaining percentage (100% - 11.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Genmab:

  • The MRQ is 0.113. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.113. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.113TTM0.1130.000
TTM0.113YOY0.101+0.012
TTM0.1135Y0.110+0.002
5Y0.11010Y0.1100.000
1.4.2. Debt to Equity Ratio

Measures if Genmab is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Genmab to the  industry mean.
  • A Debt to Equity ratio of 12.7% means that company has kr0.13 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Genmab:

  • The MRQ is 0.127. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.127. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.127TTM0.1270.000
TTM0.127YOY0.112+0.015
TTM0.1275Y0.124+0.002
5Y0.12410Y0.1240.000

2. Market Valuation of Genmab

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Genmab generates.

  • Above 15 is considered overpriced but always compare Genmab to the  industry mean.
  • A PE ratio of 62.04 means the investor is paying kr62.04 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Genmab:

  • The EOD is 83.333. Neutral. Compare to industry.
  • The MRQ is 62.042. Neutral. Compare to industry.
  • The TTM is 182.910. Seems overpriced? -1
Trends
Current periodCompared to+/- 
EOD83.333MRQ62.042+21.291
MRQ62.042TTM182.910-120.868
TTM182.910YOY292.923-110.013
TTM182.9105Y243.426-60.516
5Y243.42610Y243.4260.000
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Genmab.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Genmab:

  • The MRQ is 231.829. Seems overpriced? -1
  • The TTM is -322.877. Very Bad. -2
Trends
Current periodCompared to+/- 
MRQ231.829TTM-322.877+554.705
TTM-322.877YOY924.637-1,247.514
TTM-322.8775Y300.880-623.757
5Y300.88010Y300.8800.000

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Genmab is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to industry mean).
  • A PB ratio of 7.53 means the investor is paying kr7.53 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Genmab:

  • The EOD is 10.109. Seems overpriced? -1
  • The MRQ is 7.526. Seems overpriced? -1
  • The TTM is 7.583. Seems overpriced? -1
Trends
Current periodCompared to+/- 
EOD10.109MRQ7.526+2.583
MRQ7.526TTM7.583-0.057
TTM7.583YOY8.117-0.534
TTM7.5835Y7.894-0.311
5Y7.89410Y7.8940.000
2. Total Gains per Share

2.4. Latest News of Genmab

Does Genmab still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Genmab to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2022-11-23
20:56
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsRead
2022-11-21
20:44
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsRead
2022-11-21
20:39
Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in GenmabRead
2022-11-21
14:00
Genmab Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (BLA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)Read
2022-11-14
18:30
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsRead
2022-11-10
14:27
Genmab to Present at Jefferies London Healthcare ConferenceRead
2022-11-09
17:01
Genmab Announces Financial Results for the First Nine Months of 2022Read

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Genmab compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share----0%10.463-100%35.794-100%35.794-100%
Book Value Growth--0.8590.8590%0.864-1%0.8610%0.8610%
Book Value Per Share--322.145322.1450%305.683+5%310.178+4%310.178+4%
Book Value Per Share Growth----0%0.034-100%0.017-100%0.017-100%
Current Ratio--9.61813.635-29%14.360-33%13.402-28%13.402-28%
Debt To Asset Ratio--0.1130.1130%0.101+12%0.110+2%0.110+2%
Debt To Equity Ratio--0.1270.1270%0.112+13%0.124+2%0.124+2%
Dividend Per Share----0%-0%-0%-0%
Eps--39.07821.393+83%10.875+259%15.235+157%15.235+157%
Eps Growth--0.2680.060+348%-0.342+228%-0.141+153%-0.141+153%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Net Profit Margin----0%0.379-100%0.203-100%0.203-100%
Operating Margin----0%0.196-100%0.087-100%0.087-100%
Operating Ratio----0%-0%-0%-0%
Pb Ratio10.109+26%7.5267.583-1%8.117-7%7.894-5%7.894-5%
Pe Ratio83.333+26%62.042182.910-66%292.923-79%243.426-75%243.426-75%
Peg Ratio--231.829-322.877+239%924.637-75%300.880-23%300.880-23%
Price Per Share3256.500+26%2424.5002442.750-1%2482.250-2%2445.722-1%2445.722-1%
Profit Growth--89.65186.714+3%81.038+11%83.876+7%83.876+7%
Quick Ratio--1.6572.050-19%20.963-92%11.609-86%11.609-86%
Return On Assets--0.1080.059+83%0.032+238%0.043+150%0.043+150%
Return On Equity--0.1210.066+83%0.035+242%0.048+150%0.048+150%
Total Gains Per Share----0%10.463-100%35.794-100%35.794-100%
Usd Book Value--3007570500.0003007570500.0000%2852599725.000+5%2894609000.000+4%2894609000.000+4%
Usd Book Value Change Per Share----0%1.478-100%5.058-100%5.058-100%
Usd Book Value Per Share--45.51945.5190%43.193+5%43.828+4%43.828+4%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--5.5223.023+83%1.537+259%2.153+157%2.153+157%
Usd Price Per Share460.143+26%342.582345.161-1%350.742-2%345.581-1%345.581-1%
Usd Profit--364836600.000199727550.000+83%101488725.000+259%142194900.000+157%142194900.000+157%
Usd Revenue----0%279314775.000-100%151206700.000-100%151206700.000-100%
Usd Total Gains Per Share----0%1.478-100%5.058-100%5.058-100%
 EOD+1 -3MRQTTM+10 -4YOY+14 -145Y+14 -1410Y+14 -14

3.2. Fundamental Score

Let's check the fundamental score of Genmab based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1583.333
Price to Book Ratio (EOD)Between0-110.109
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.657
Current Ratio (MRQ)Greater than19.618
Debt to Asset Ratio (MRQ)Less than10.113
Debt to Equity Ratio (MRQ)Less than10.127
Return on Equity (MRQ)Greater than0.150.121
Return on Assets (MRQ)Greater than0.050.108
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Genmab based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5068.456
Ma 20Greater thanMa 503,170.125
Ma 50Greater thanMa 1002,942.930
Ma 100Greater thanMa 2002,783.553
OpenGreater thanClose3,256.500
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2022-09-30. Currency in DKK. All numbers in thousands.

Summary
 As reported
Total Liabilities -
Total Stockholder Equity+ -
Total Assets = -

Assets

Total Assets-
Total Current Assets28,739,000
Long-term Assets28,739,000
Total Current Assets
Net Receivables 4,951,000
Total Current Assets  (as reported)28,739,000
Total Current Assets  (calculated)4,951,000
+/- 23,788,000
Long-term Assets
Property Plant Equipment 1,289,000
Long-term Assets  (as reported)0
Long-term Assets  (calculated)1,289,000
+/- 1,289,000

Liabilities & Shareholders' Equity

Total Current Liabilities2,988,000
Long-term Liabilities-
Total Stockholder Equity-
Total Current Liabilities
Other Current Liabilities 2,909,000
Total Current Liabilities  (as reported)2,988,000
Total Current Liabilities  (calculated)2,909,000
+/- 79,000
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock66,000
Other Stockholders Equity 151,000
Total Stockholder Equity (as reported)0
Total Stockholder Equity (calculated)217,000
+/- 217,000
Other
Net Tangible Assets 26,457,000



Balance Sheet

Currency in DKK. All numbers in thousands.

 Trend2022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-30
> Total Assets 
21,522,000
21,143,000
22,210,000
22,483,000
23,985,000
0
0
0
0
000023,985,00022,483,00022,210,00021,143,00021,522,000
   > Total Current Assets 
19,504,000
18,791,000
19,937,000
20,304,000
21,954,000
22,736,000
23,175,000
25,491,000
28,739,000
28,739,00025,491,00023,175,00022,736,00021,954,00020,304,00019,937,00018,791,00019,504,000
       Cash And Cash Equivalents 
8,892,000
7,260,000
7,892,000
9,477,000
8,729,000
0
0
0
0
00008,729,0009,477,0007,892,0007,260,0008,892,000
       Short-term Investments 
8,577,000
8,819,000
10,191,000
8,398,000
10,014,000
0
0
0
0
000010,014,0008,398,00010,191,0008,819,0008,577,000
       Net Receivables 
2,035,000
2,463,000
1,854,000
2,429,000
3,211,000
3,398,000
3,187,000
3,876,000
4,951,000
4,951,0003,876,0003,187,0003,398,0003,211,0002,429,0001,854,0002,463,0002,035,000
   > Long-term Assets 000000000
       Property Plant Equipment 
730,000
736,000
842,000
919,000
957,000
975,000
975,000
1,238,000
1,289,000
1,289,0001,238,000975,000975,000957,000919,000842,000736,000730,000
       Intangible Assets 
385,000
338,000
317,000
297,000
275,000
0
0
0
0
0000275,000297,000317,000338,000385,000
> Total Liabilities 
3,045,000
2,022,000
2,115,000
2,231,000
2,700,000
0
0
0
0
00002,700,0002,231,0002,115,0002,022,0003,045,000
   > Total Current Liabilities 
2,258,000
1,253,000
1,293,000
1,351,000
1,830,000
1,568,000
1,339,000
1,944,000
2,988,000
2,988,0001,944,0001,339,0001,568,0001,830,0001,351,0001,293,0001,253,0002,258,000
       Accounts payable 
0
0
0
0
0
350,000
0
0
0
000350,00000000
       Other Current Liabilities 
0
0
0
1,292,000
1,767,000
860,000
1,279,000
1,864,000
2,909,000
2,909,0001,864,0001,279,000860,0001,767,0001,292,000000
   > Long-term Liabilities 000000000
       Other Liabilities 
0
0
0
496,000
496,000
500,000
500,000
496,000
491,000
491,000496,000500,000500,000496,000496,000000
> Total Stockholder Equity
18,477,000
19,121,000
20,095,000
20,252,000
21,285,000
0
0
0
0
000021,285,00020,252,00020,095,00019,121,00018,477,000
   Common Stock
65,000
66,000
66,000
66,000
66,000
66,000
66,000
66,000
66,000
66,00066,00066,00066,00066,00066,00066,00066,00065,000
   Retained Earnings 
6,537,000
7,161,000
8,020,000
8,164,000
9,139,000
10,020,000
10,512,000
12,243,000
14,299,000
14,299,00012,243,00010,512,00010,020,0009,139,0008,164,0008,020,0007,161,0006,537,000
   Capital Surplus 
11,875,000
11,894,000
11,914,000
11,940,000
11,996,000
0
0
0
0
000011,996,00011,940,00011,914,00011,894,00011,875,000
   Treasury Stock000000000
   Other Stockholders Equity 
0
0
95,000
82,000
84,000
81,000
97,000
110,000
151,000
151,000110,00097,00081,00084,00082,00095,00000



Balance Sheet

Currency in DKK. All numbers in thousands.




Cash Flow

Currency in DKK. All numbers in thousands.




Income Statement

Currency in DKK. All numbers in thousands.


Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue-
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense--
Operating Income-0
 
Operating Expense (+$)
Research Development-
Selling General Administrative-
Selling And Marketing Expenses-
Operating Expense-0
 
Net Interest Income (+$)
Interest Income-
Interest Expense-0
Net Interest Income-0
 
Pretax Income (+$)
Operating Income-
Net Interest Income-
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-0
EBIT - interestExpense = 3,018,000
975,000
0
Interest Expense0
Earnings Before Interest and Taxes (ebit)3,018,0000
Earnings Before Interest and Taxes (ebitda)-
 
After tax Income (+$)
Income Before Tax-
Tax Provision--
Net Income From Continuing Ops-0
Net Income-
Net Income Applicable To Common Shares3,008,000
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-0
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
ESLOY.PINK
1 minute ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ESLOY.PINK.

ESLOY.PINK Daily Candlestick Chart
EMSA.LSE
5 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of EMSA.LSE.

EMSA.LSE Daily Candlestick Chart
EMUU.LSE
5 minutes ago

I found you a Golden Cross on the daily chart of EMUU.LSE.

EMUU.LSE Daily Candlestick Chart
EMGA.LSE
6 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of EMGA.LSE.

EMGA.LSE Daily Candlestick Chart
EMES.LSE
6 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of EMES.LSE.

EMES.LSE Daily Candlestick Chart
EMDD.LSE
7 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of EMDD.LSE.

EMDD.LSE Daily Candlestick Chart
EMIG.LSE
7 minutes ago

I found you a Death Cross on the daily chart of EMIG.LSE.

EMIG.LSE Daily Candlestick Chart
ELBM.NASDAQ
9 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of ELBM.NASDAQ.

ELBM.NASDAQ Daily Candlestick Chart
DS2P.LSE
21 minutes ago

I found you a Death Cross on the daily chart of DS2P.LSE.

DS2P.LSE Daily Candlestick Chart
DQD.TO
22 minutes ago

I found you a Golden Cross on the daily chart of DQD.TO.

DQD.TO Daily Candlestick Chart
DNGDF.PINK
24 minutes ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of DNGDF.PINK.

DNGDF.PINK Daily Candlestick Chart
CU2G.LSE
32 minutes ago

I found you a Death Cross on the daily chart of CU2G.LSE.

CU2G.LSE Daily Candlestick Chart
CONTAINE.BSE
35 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CONTAINE.BSE.

CONTAINE.BSE Daily Candlestick Chart
CNXMEDIA.INDX
36 minutes ago

I found you a Golden Cross on the daily chart of CNXMEDIA.INDX.

CNXMEDIA.INDX Daily Candlestick Chart
CNCT.PINK
37 minutes ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of CNCT.PINK.

CNCT.PINK Daily Candlestick Chart
CNA.LSE
37 minutes ago

I found you a Golden Cross on the daily chart of CNA.LSE.

CNA.LSE Daily Candlestick Chart
CGUSY.PINK
42 minutes ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of CGUSY.PINK.

CGUSY.PINK Daily Candlestick Chart
CENQ.NASDAQ
43 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CENQ.NASDAQ.

CENQ.NASDAQ Daily Candlestick Chart
CAVR.PINK
45 minutes ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of CAVR.PINK.

CAVR.PINK Daily Candlestick Chart
CAR.LSE
45 minutes ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of CAR.LSE.

CAR.LSE Daily Candlestick Chart
BVIC.LSE
48 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of BVIC.LSE.

BVIC.LSE Daily Candlestick Chart
BRGC.PINK
52 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of BRGC.PINK.

BRGC.PINK Daily Candlestick Chart
BLBLIMITED.BSE
55 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of BLBLIMITED.BSE.

BLBLIMITED.BSE Daily Candlestick Chart
BIOR.NASDAQ
57 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of BIOR.NASDAQ.

BIOR.NASDAQ Daily Candlestick Chart